HIGHLIGHTS
- What: The authors aimed to characterize the immunological repertoire of AML patients treated with VEN in combination with HMA by focusing on the modulation of IC receptors` expression. The study had new evidence in support of the ability of VEN to modulate immune cell composition and phenotype.
- Who: Omer Jamy et al. from the University of Alabama at Birmingham, United States have published the paper: Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-speci c effect on non-suppressive regulatory T cells and bona de PD . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.